Indication
IDH2 Mutation
2 clinical trials
4 products
Clinical trial
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 MutationStatus: Completed, Estimated PCD: 2023-05-30
Product
RuxolitinibProduct
EnasidenibClinical trial
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 MutationsStatus: Completed, Estimated PCD: 2023-10-31
Product
BGB-290Product
TMZ